Last reviewed · How we verify

NCT03737799: StartRight

StartRight: Getting the Right Classification and Treatment From Diagnosis in Adults With Diabetes

Active, enrolled Last updated 4 June 2024
What this trial tests

trial in Diabetes Mellitus in 1,815 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 August 2016
Primary endpoint
30 June 2024
31 December 2024

Quick facts

Lead sponsorRoyal Devon and Exeter NHS Foundation Trust
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment1,815
Start date1 August 2016
Primary completion30 June 2024
Estimated completion31 December 2024
Sites1 location across United Kingdom

Conditions studied

Sponsor

Royal Devon and Exeter NHS Foundation Trust

Who can join

18 and older, any sex, with Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to achieve more accurate early classification of diabetes and identification of which patients will rapidly require insulin treatment. The investigators will recruit 1200 participants who have been diagnosed with diabetes in the last year and were aged between 18 and 50 years at the time of diagnosis. The investigators will recruit an additional cohort of 800 participants diagnosed after age 50. The investigators will record clinical features and biomarkers that may help us to determine diabetes type at diagnosis and follow participants for 3 years to assess the development of severe insulin deficiency (measured using C-peptide) and insulin requirement. The investigators will assess utility of clinical features and additional biomarkers in identifying patients with rapid progression to insulin requirement. Findings will be integrated into a freely available clinical prediction models to assist classification of diabetes at diagnosis.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18-50 years.
    Lynam A, McDonald T, Hill A, Dennis J, et al · · 2019 · cited 53× · PMID 31558459 · DOI 10.1136/bmjopen-2019-031586
  2. Histological validation of a type 1 diabetes clinical diagnostic model for classification of diabetes.
    Carr ALJ, Perry DJ, Lynam AL, Chamala S, et al · · 2020 · cited 16× · PMID 32634859 · DOI 10.1111/dme.14361
  3. Age of Diagnosis Does Not Alter the Presentation or Progression of Robustly Defined Adult-Onset Type 1 Diabetes.
    Thomas NJ, Hill AV, Dayan CM, Oram RA, et al · · 2023 · cited 12× · PMID 36802355 · DOI 10.2337/dc22-2159
  4. 56<sup>th</sup> EASD Annual Meeting of the European Association for the Study of Diabetes : 21-25 September 2020.
    · 2020 · cited 9× · PMID 32840677 · DOI 10.1007/s00125-020-05221-5
  5. 58<sup>th</sup> EASD Annual Meeting of the European Association for the Study of Diabetes : Stockholm, Sweden, 19 - 23 September 2022.
    · 2022 · cited 6× · PMID 35920845 · DOI 10.1007/s00125-022-05755-w
  6. Amphibians as a source of bioactive antioxidant peptides: Emerging insights and therapeutic potential.
    Zhu YY, Zhao LM, Jia XY, Liao GJ, et al · · 2025 · PMID 41017405 · DOI 10.24272/j.issn.2095-8137.2025.127

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus

Currently open trials in the same condition.

Other Royal Devon and Exeter NHS Foundation Trust trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03737799.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing